Immunomodulation vs. Immunostimulation: Why It Matters for Autoimmunity

Mushrooms & Autoimmune Disease

IL-17: reduced by reishi in lupus models, not increased

Reishi (Ganoderma lucidum) decreased IL-17 and shifted the Treg/Th17 ratio toward regulatory immune balance in lupus mouse models. This is an immune-suppressing effect in an autoimmune context, not immune stimulation; it's the evidence behind why researchers classify mushrooms as immunomodulators rather than immunostimulants.

Bhardwaj et al., Recent Patents Inflammation & Allergy Drug Discovery, 2014

Immunomodulator

the classification assigned to medicinal mushrooms in a 2021 Journal of Autoimmunity review (the primary autoimmunity science journal) by Motta, Gershwin, and Selmi, based on their context-dependent, bidirectional immune effects

Bidirectional

the property that allows the same mushroom compound to activate an underactive immune response or suppress an overactive one depending on the existing immune state; this is the mechanism underlying the immunomodulator classification

VCAM-1 inhibited

Antcin K, a triterpenoid from Antrodia cinnamomea, blocked monocyte adhesion to RA synovial tissue by inhibiting VCAM-1, a specific immune-suppressing effect in joint inflammation, not a stimulating one (Achudhan et al., 2022)

Bhardwaj et al., Recent Patents Inflammation & Allergy Drug Discovery, 2014

View as image ↗

The most common concern about medicinal mushrooms and autoimmune disease is straightforward: if mushrooms stimulate the immune system, and autoimmune disease is caused by an overactive immune system, then mushrooms could make autoimmune conditions worse. This reasoning is intuitive and widely repeated.

It rests on a category error.

Medicinal mushrooms are not immunostimulants. The research classifies them as immunomodulators, a functionally distinct category with a different relationship to the immune system. The difference between these two classifications is precisely what determines whether the concern about autoimmunity is justified, overstated, or more nuanced than a yes/no answer can capture.

For the pillar overview of beta-glucan immune research, see mushroom beta-glucans and immunity: the complete research guide.

What Immunostimulation Means, and Why the Concern Is Reasonable

Immunostimulation is a straightforward concept: it means increasing immune system activity. Vaccines are immunostimulants. Some infectious disease treatments are immunostimulants. Certain compounds derived from bacteria reliably push the immune system into a more active state.

The concern about immunostimulation in autoimmune disease is grounded in a real problem. Autoimmune conditions (rheumatoid arthritis, lupus, multiple sclerosis, and others) involve an immune system that has misidentified the body's own tissues as threats and is attacking them. Anything that broadly increases immune activity might, in theory, increase the intensity of that misdirected attack.

This is why people with autoimmune conditions are often advised to be cautious about supplements marketed as "immune-boosting." The concern is logically coherent and not dismissible as excessive caution.

The question is whether medicinal mushrooms, when studied as actual compounds in cell and animal research, behave like immunostimulants. The research says they do not.

What Immunomodulation Means: Bidirectional Adjustment

Immunomodulation is a more complex concept than immunostimulation. An immunomodulator does not simply push the immune system up or down. It adjusts immune responses toward appropriate function, with the direction of adjustment depending on the existing immune state.

In a practical sense: the same compound that activates NK cells and macrophages in a person with an underactive immune response might suppress pro-inflammatory cytokines in a person with an overactive autoimmune response.

This bidirectional capacity is not theoretical. Lull and colleagues documented it in a 2005 review of fungal metabolites and their immune effects, establishing the framework that has organized subsequent research: fungal compounds produce both anti-inflammatory and immune-activating effects depending on the immunological context, not uniform pro-immune stimulation.^[1]

The mechanism underlying this bidirectionality involves two distinct molecular pathways that mushroom compounds can activate:

The activation pathway: Beta-glucans bind to Dectin-1 and TLR2 receptors on immune cells, triggering the innate immune cascade. This is the pathway responsible for the immune-activating effects documented in infection and cancer research.

The suppression pathway: Triterpenoids (particularly in reishi and Antrodia species) inhibit NF-κB signaling. NF-κB is a master transcription factor for inflammatory and immune gene expression. Inhibiting NF-κB reduces pro-inflammatory cytokine production, including the cytokines most relevant to autoimmune pathology.

These two pathways coexist in mushrooms that contain both polysaccharides and triterpenoids. Which pathway dominates in a given context depends on the specific compound, the concentration, the tissue type, and the existing immune state.

What the Journal of Autoimmunity Concluded

The most authoritative available source for how the scientific establishment views mushrooms in autoimmune contexts is a 2021 review published in Journal of Autoimmunity by Motta, Gershwin, and Selmi.^[2]

Journal of Autoimmunity is the primary peer-reviewed journal for autoimmune disease research. A paper appearing in this journal on the subject of mushrooms and immunity was reviewed by autoimmunity specialists before publication, not by general immunologists.

The review's conclusions: medicinal mushrooms function as immunomodulators with context-dependent, bidirectional immune effects. The mechanisms they documented include beta-glucan receptor activation of dendritic cells and macrophages (activation pathway), cytokine profile modulation (including reductions in pro-inflammatory cytokines relevant to autoimmunity), and induction of regulatory T cells (Tregs, the immune cells that suppress autoimmune activity).

Treg induction is particularly significant. Regulatory T cells are deficient in many autoimmune conditions. A treatment that induces more Tregs is not stimulating the immune system broadly; it is increasing the specific immune cell population whose job is to suppress excessive immune activity.

The Motta 2021 review does not conclude that mushrooms are safe for autoimmune patients or that they should be recommended. It concludes that the immunostimulant categorization is incorrect and that the evidence shows context-dependent regulation rather than uniform activation. This is a scientifically meaningful distinction, even if it does not resolve all clinical questions.

The Evidence for Immune Suppression in Autoimmune Contexts

The most direct evidence that some mushroom compounds suppress rather than stimulate immunity in autoimmune tissue comes from two research lines.

Reishi and the Treg/Th17 axis in lupus. In lupus mouse models, Ganoderma lucidum (reishi) decreased IL-17 production and shifted the balance between Th17 cells (pro-inflammatory, elevated in lupus) and regulatory T cells (Treg, suppressive) toward the regulatory side.^[3] IL-17 is one of the primary cytokines driving autoimmune tissue damage, particularly in lupus nephritis (kidney involvement). A compound that reduces IL-17 in a lupus model is acting as an immune suppressant in that context, not an immune activator.

Antcin K and monocyte recruitment in RA. Achudhan and colleagues demonstrated in 2022 that Antcin K (a triterpenoid from Antrodia cinnamomea) inhibited VCAM-1-dependent monocyte adhesion in human rheumatoid arthritis synovial fibroblasts.^[4] VCAM-1 (vascular cell adhesion molecule 1) is the surface protein that immune cells attach to before entering inflamed joint tissue. Blocking VCAM-1 reduces immune cell infiltration into joints, a mechanism of immune cell traffic suppression in the tissue most affected by RA.

Both examples show specific immune-suppressing effects in autoimmune-relevant contexts, not the uniform immune amplification that the immunostimulant concern predicts.

For the full condition-specific evidence on RA, lupus, and multiple sclerosis, see mushrooms for lupus, RA, and MS: research across conditions.

The Critical Nuance: Not All Mushrooms Lean the Same Direction

The immunomodulator classification describes medicinal mushrooms as a category. Individual species differ in how they express that bidirectionality.

The ratio of polysaccharides (beta-glucans, which drive the activation pathway) to triterpenoids (which drive the suppression pathway) varies considerably between species. Species with high triterpenoid content (reishi and Antrodia cinnamomea being the clearest examples) lean more toward the immune-regulatory and anti-inflammatory direction. These are the species with the most direct evidence for immune-suppressing effects in autoimmune-relevant contexts.

Species with high polysaccharide content and low triterpenoid content lean more toward immune activation. Turkey tail (Trametes versicolor) and its PSK compound, for example, have extensive evidence for NK cell activation and anti-cancer immune activity. This activating profile may be appropriate in cancer or infection contexts and less appropriate for autoimmune conditions where immune activation is already excessive.

Chaga (Inonotus obliquus) has potent immune-stimulating activity well documented in cell studies and animal models. It has the least direct evidence for immune-balancing effects in autoimmune contexts.

The clinical implication is that "medicinal mushrooms" is not a uniform category for autoimmune purposes, even within the immunomodulator classification. The species matters.

For how different mushrooms affect cytokine profiles across immune conditions, see medicinal mushrooms and cytokine balance. For the T-cell differentiation mechanism behind Treg induction, see mushroom polysaccharides and T-cell differentiation: training adaptive immunity.

What the Immunomodulator Classification Does Not Resolve

Being an immunomodulator rather than an immunostimulant is necessary but not sufficient for safety in autoimmune conditions.

No human clinical trial has tested any mushroom supplement for safety or efficacy in any autoimmune condition. The evidence described in this article and across this cluster is entirely preclinical (cell culture and animal models). The jump from animal model data to human clinical outcomes is substantial and frequently unreliable.

The potential for interaction between mushroom compounds and immunosuppressive medications (methotrexate, hydroxychloroquine, biologic therapies like TNF inhibitors) is unknown. Mushroom compounds that shift the Th17/Treg balance may theoretically interact with medications targeting the same pathways.

The immunomodulator classification is meaningful for understanding why the blanket concern about autoimmunity is not well-supported mechanistically. It is not a clinical safety clearance. For the condition-specific safety considerations, see the safety of mushroom supplements for autoimmune patients and mushrooms and autoimmune disease: can they help without overstimulating?.

For the mechanistic explanation of how the dual activation/suppression capacity operates at the cellular level, see mushrooms for autoimmune disease: when immune stimulation becomes immune balancing.

The Bottom Line

Medicinal mushrooms are immunomodulators, not immunostimulants: they adjust immune responses bidirectionally depending on context rather than uniformly pushing immunity upward. A 2021 Journal of Autoimmunity review classified them in this category based on mechanisms including beta-glucan receptor activation, cytokine modulation, and Treg induction (Motta et al., 2021). The foundational bidirectional framework was established in 2005 (Lull et al., 2005). Reishi decreases IL-17 and shifts Treg/Th17 balance toward regulation in lupus models (Bhardwaj et al., 2014), and Antcin K suppresses VCAM-1-dependent monocyte recruitment in RA synovial tissue (Achudhan et al., 2022). Species with higher triterpenoid content (reishi, Antrodia) lean toward immune regulation; those with predominantly polysaccharide activity lean toward activation. No human clinical trials exist for any mushroom in any autoimmune condition.

Frequently Asked Questions

What is the difference between immunomodulation and immunostimulation?

Immunostimulation uniformly increases immune activity. Immunomodulation adjusts immune responses bidirectionally toward appropriate balance, with the direction depending on the existing immune state. A 2021 Journal of Autoimmunity review classified medicinal mushrooms as immunomodulators based on their context-dependent effects, including both immune activation in underactive states and cytokine reduction in overactive conditions (Motta et al., 2021). The same compound that activates NK cells in cancer contexts can reduce pro-inflammatory cytokines in autoimmune tissue.

Can immunomodulators make autoimmune disease worse?

The immunomodulator classification reduces but does not eliminate the concern. An immunomodulator that predominantly activates immunity (turkey tail's PSK, which strongly activates NK cells) could be more concerning for autoimmune patients than one that predominantly regulates or suppresses immunity (reishi's triterpenoids, which reduce IL-17 and shift Treg balance). No human clinical data establishes safety for any mushroom in autoimmune conditions. The immunostimulant concern is based on a category error; mushrooms are not immunostimulants; but the immunomodulator category is not uniform across species.

Why are mushrooms called immunomodulators?

Because they contain two distinct compound classes that operate through opposite immune pathways. Polysaccharides (beta-glucans) activate immunity by binding Dectin-1 and TLR2 receptors. Triterpenoids (found in reishi, Antrodia, and others) suppress immunity by inhibiting NF-κB signaling and reducing pro-inflammatory cytokine production. This dual capacity creates context-dependent effects: the same mushroom can activate an underactive immune response or suppress an overactive one, depending on which pathway is most relevant to the existing immune state. Lull and colleagues documented this bidirectional framework in 2005 (Mediators Inflamm).

What does it mean for an immune supplement to be bidirectional?

A bidirectional supplement adjusts immune function toward balance rather than uniformly up or down. In practical terms: a bidirectional compound that activates NK cells in a person with low immune function may simultaneously reduce pro-inflammatory cytokines in a person with excessive immune activity. The direction of the net effect depends on the existing immune environment. This is why the same mushroom compound can show anti-cancer immune activation in one study and anti-inflammatory suppression in another; both effects are real and both are consistent with the immunomodulator classification.

Are beta-glucans safe for autoimmune conditions?

Beta-glucans specifically activate immunity through Dectin-1 and TLR2 receptor binding, the activation arm of the bidirectional response. The suppressive effects in autoimmune research come primarily from triterpenoids, not beta-glucans. A supplement that is predominantly beta-glucan (low triterpenoid) leans more toward immune activation and may be a less appropriate choice for autoimmune conditions than a triterpenoid-rich species like reishi. No human clinical data answers this question definitively for any mushroom supplement in any autoimmune condition.

Sources & References

1. 1RTHM-00166·Lull, Cristina et al. (2005). “Antiinflammatory and immunomodulating properties of fungal metabolites..” Mediators of inflammation.Study breakdown →PubMed →↩
2. 2RTHM-00709·Motta, Francesca et al. (2021). “Mushrooms and immunity..” Journal of autoimmunity.Study breakdown →PubMed →↩
3. 3RTHM-00578·Bhardwaj, Neha et al. (2014). “Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum..” Recent patents on inflammation & allergy drug discovery.Study breakdown →PubMed →↩
4. 4RTHM-00738·Achudhan, David et al. (2022). “Antcin K inhibits VCAM-1-dependent monocyte adhesion in human rheumatoid arthritis synovial fibroblasts..” Food & nutrition research.Study breakdown →PubMed →↩